Compositions and methods for inhibition of pathogenic bacterial growth

Inventors

Cook, David N. • Zhang, Han • D'Onofrio, Anthony Mario • Berry, David Arthur • McKenzie, Mary-Jane Lombardo • Aunins, John Grant • McKenzie, Gregory • Ohsumi, Toshiro K.

Assignees

Seres Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11185562-B2

Patent

Publication Date

2021-11-30

Expiration Date


Abstract

Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients.

Core Innovation

The invention provides a composition comprising a population of bacteria, an excipient, and an enteric coating, formulated for oral administration to a mammalian subject. The bacteria comprise spore forming bacteria including at least a first and a second spore forming species of bacteria.

The first spore forming species is Clostridium bolteae having a 16S sequence having at least 97% sequence identity to SEQ ID No: 559, and the second spore forming species is Clostridium orbiscindens having a 16S sequence having at least 97% sequence identity to SEQ ID No: 609. The first and second spore forming species are isolated, not identical, and independently capable of proliferating in a medium comprising a nutrient under a threshold concentration below a concentration of the nutrient required for Clostridium difficile proliferation.

The document further relates to orally administered spore forming compositions using defined excipient components and additional Clostridium species with corresponding 16S identity constraints. It also describes using the orally administered spore-forming composition to reduce Clostridium difficile growth, proliferation, and/or colonization.

Claims Coverage

The coverage centers on one independent claim directed to an orally administered, enteric-coated composition of spore forming bacteria defined by specific 16S sequence identity criteria and by nutrient-threshold independent proliferation relative to Clostridium difficile. Dependent claims further refine excipient formulation, add optional additional Clostridium species, and include quantitative growth-rate comparisons and method aspects directed to reducing Clostridium difficile growth, proliferation, and/or colonization.

Orally administered enteric-coated spore bacterial composition

A composition comprising a population of bacteria, an excipient, and an enteric coating, formulated for oral administration to a mammalian subject.

Dual Clostridium spore species defined by 16S identity

The bacteria consist of spore forming bacteria comprising at least a first and a second spore forming species of bacteria, wherein the first spore forming species is Clostridium bolteae comprising a 16S sequence having at least 97% sequence identity to SEQ ID No: 559 and the second spore forming species is Clostridium orbiscindens comprising a 16S sequence having at least 97% sequence identity to SEQ ID No: 609.

Isolated, non-identical, independently proliferating under nutrient-threshold conditions

The first and second spore forming species of bacteria are isolated, not identical, and independently capable of proliferating in a medium comprising a nutrient with a threshold concentration of the nutrient below a concentration of the nutrient required for Clostridium difficile proliferation in the medium.

Optional growth-rate superiority versus Clostridium difficile

Two independently proliferating spore forming bacterial species grow at a rate at least 10% greater than Clostridium difficile in a medium containing one or more carbohydrate nutrients.

Optional excipient component categories

The excipient is chosen from buffering agents, preservatives, stabilizers, binders, compaction agents, lubricants, dispersion enhancers, disintegration agents, flavoring agents, sweeteners, and coloring agents.

Optional additional spore forming Clostridium species by 16S identity

The composition further includes a third spore forming bacterial species, Clostridium scindens, characterized by a 16S sequence having at least 97% sequence identity to SEQ ID No: 623.

Overall, the claim coverage centers on an orally administered, enteric-coated bacterial spore composition defined by specific 16S sequence identity constraints and by independent proliferation under nutrient-threshold conditions relative to Clostridium difficile. Dependent claim features further narrow formulation components, optionally add additional Clostridium species with defined 16S identity, and may impose growth-rate superiority and specific proliferation determination constraints.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Preclinical mouse prophylaxis and hamster prophylaxis/relapse prevention models for C. difficile.

Early clinical examples for recurrent C. difficile using ethanol-treated and gradient-purified spores.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.